 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of [0m
[34mmortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase or decrease the risk of [0m
[32mmortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ATENOLOL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ATENOLOL: indications_and_usage: INDICATIONS AND USAGE Hypertension Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk [0m
[31mof fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of [0m
[31mpharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, [0m
[31mantithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than [0m[1;31m1[0m[31m drug to achieve blood pressure goals. For specific advice on goals and [0m
[31mmanagement, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood [0m
[31mPressure [0m[1;31m([0m[31mJNC[0m[1;31m)[0m[31m. ATENOLOL: indications_and_usage: Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized [0m
[31mcontrolled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely[0m
[31mresponsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular [0m
[31mmortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so [0m
[31mthat even modest reductions of severe hypertension can provide substantial benefit. ATENOLOL: indications_and_usage: Relative risk reduction from blood pressure reduction is similar across populations[0m
[31mwith varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension [0m[1;31m([0m[31mfor example, patients with diabetes or hyperlipidemia[0m[1;31m)[0m[31m, and such [0m
[31mpatients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects [0m[1;31m([0m[31mas monotherapy[0m[1;31m)[0m[31m in black patients,[0m
[31mand many antihypertensive drugs have additional approved indications and effects [0m[1;31m([0m[31me.g., on angina, heart failure, or diabetic kidney disease[0m[1;31m)[0m[31m. These considerations may guide selection of therapy. [0m
[31mAtenolol may be administered with other antihypertensive agents. Angina Pectoris Due to Coronary Atherosclerosis Atenolol is indicated for the long-term management of patients with angina pectoris. [0m
[31mATENOLOL: indications_and_usage: Acute Myocardial Infarction Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce[0m
[31mcardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m. In general, there is no [0m
[31mbasis for treating patients like those who were excluded from the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31mblood pressure less than [0m[1;31m100[0m[31m mm Hg systolic, heart rate less than [0m[1;31m50[0m[31m bpm[0m[1;31m)[0m[31m or have other reasons to avoid beta blockade. [0m
[31mAs noted above, some subgroups [0m[1;31m([0m[31me.g., elderly patients with systolic blood pressure below [0m[1;31m120[0m[31m mm Hg[0m[1;31m)[0m[31m seemed less likely to benefit.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: boxed_warning: In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to [0m
[31mcardiac failure. At the first sign or symptom of impending cardiac failure, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely. [0m
[31mIf cardiac failure continues despite adequate treatment, atenolol should be withdrawn [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Cessation of Therapy with Atenolol: Patients with coronary artery disease, who [0m
[31mare being treated with atenolol, should be advised against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have[0m
[31mbeen reported in angina patients following the abrupt discontinuation of therapy with beta blockers. The last two complications may occur with or without preceding exacerbation of the angina pectoris.[0m
[31mATENOLOL: boxed_warning: As with other beta blockers, when discontinuation of atenolol is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. If the[0m
[31mangina worsens or acute coronary insufficiency develops, it is recommended that atenolol be promptly reinstituted, at least temporarily. Because coronary artery disease is common and may be [0m
[31munrecognized, it may be prudent not to discontinue atenolol therapy abruptly even in patients treated only for hypertension [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: precautions: PRECAUTIONS General Patients already on a beta blocker must be evaluated carefully before atenolol is administered. Initial and subsequent atenolol dosages can be [0m
[31madjusted downward depending on clinical observations including pulse and blood pressure. Atenolol may aggravate peripheral arterial circulatory disorders. Impaired Renal Function The drug should be [0m
[31mused with caution in patients with impaired renal function [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Drug Interactions Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given [0m
[31mwith beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia, which may produce [0m
[31mvertigo, syncope, or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. ATENOLOL: precautions: Disopyramide is a Type I [0m
[31mantiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta blockers. [0m
[31mAmiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers. Beta blockers may exacerbate the rebound hypertension, which can [0m
[31mfollow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta [0m
[31mblocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped. Concomitant use of prostaglandin synthase inhibiting drugs, e.g., [0m
[31mindomethacin, may decrease the hypotensive effects of beta blockers. ATENOLOL: precautions: Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., [0m
[31mTIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting. While taking beta blockers, patients with a history of [0m
[31manaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual [0m
[31mdoses of epinephrine used to treat the allergic reaction. Both digitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of[0m
[31mbradycardia. ATENOLOL: precautions: Carcinogenesis, Mutagenesis, Impairment of Fertility Two long-term [0m[1;31m([0m[31mmaximum dosing duration of [0m[1;31m18[0m[31m or [0m[1;31m24[0m[31m months[0m[1;31m)[0m[31m rat studies and one long-term [0m[1;31m([0m[31mmaximum dosing [0m
[31mduration of [0m[1;31m18[0m[31m months[0m[1;31m)[0m[31m mouse study, each employing dose levels as high as [0m[1;31m300[0m[31m mg/kg/day or [0m[1;31m150[0m[31m times the maximum recommended human antihypertensive dose * , did not indicate a carcinogenic potential [0m
[31mof atenolol. A third [0m[1;31m([0m[1;31m24[0m[31m month[0m[1;31m)[0m[31m rat study, employing doses of [0m[1;31m500[0m[31m and [0m[1;31m1[0m[31m,[0m[1;31m500[0m[31m mg/kg/day [0m[1;31m([0m[1;31m250[0m[31m and [0m[1;31m750[0m[31m times the maximum recommended human antihypertensive dose * [0m[1;31m)[0m[31m resulted in increased incidences of [0m
[31mbenign adrenal medullary tumors in males and females, mammary fibroadenomas in females, and anterior pituitary adenomas and thyroid parafollicular cell carcinomas in males. ATENOLOL: precautions: No [0m
[31mevidence of a mutagenic potential of atenolol was uncovered in the dominant lethal test [0m[1;31m([0m[31mmouse[0m[1;31m)[0m[31m, in vivo cytogenetics test [0m[1;31m([0m[31mChinese hamster[0m[1;31m)[0m[31m or Ames test [0m[1;31m([0m[31mS. typhimurium[0m[1;31m)[0m[31m. Fertility of male or female [0m
[31mrats [0m[1;31m([0m[31mevaluated at dose levels as high as [0m[1;31m200[0m[31m mg/kg/day or [0m[1;31m100[0m[31m times the maximum recommended human dose * [0m[1;31m)[0m[31m was unaffected by atenolol administration. Animal Toxicology Chronic studies employing oral [0m
[31matenolol performed in animals have revealed the occurrence of vacuolation of epithelial cells of Brunner's glands in the duodenum of both male and female dogs at all tested dose levels of atenolol [0m
[1;31m([0m[31mstarting at [0m[1;31m15[0m[31m mg/kg/day or [0m[1;31m7[0m[31m. ATENOLOL: precautions: [0m[1;31m5[0m[31m times the maximum recommended human antihypertensive dose * [0m[1;31m)[0m[31m and increased incidence of atrial degeneration of hearts of male rats at [0m[1;31m300[0m[31m but [0m
[31mnot [0m[1;31m150[0m[31m mg atenolol/kg/day [0m[1;31m([0m[1;31m150[0m[31m and [0m[1;31m75[0m[31m times the maximum recommended human antihypertensive dose * , respectively[0m[1;31m)[0m[31m. ________________________________________________________________________ * Based on [0m
[31mthe maximum dose of [0m[1;31m100[0m[31m mg/day in a [0m[1;31m50[0m[31m kg patient. Usage in Pregnancy Pregnancy Category D : See WARNINGS - Pregnancy and Fetal Injury. Nursing Mothers Atenolol is excreted in human breast milk at a [0m
[31mratio of [0m[1;31m1.5[0m[31m to [0m[1;31m6.8[0m[31m when compared to the concentration in plasma. Caution should be exercised when atenolol is administered to a nursing woman. Clinically significant bradycardia has been reported in [0m
[31mbreast fed infants. Premature infants, or infants with impaired renal function, may be more likely to develop adverse effects. ATENOLOL: precautions: Neonates born to mothers who are receiving [0m
[31matenolol at parturition or breast-feeding may be at risk for hypoglycemia and bradycardia. Caution should be exercised when atenolol is administered during pregnancy or to a woman who is [0m
[31mbreast-feeding [0m[1;31m([0m[31msee WARNING, Pregnancy and Fetal Injury [0m[1;31m)[0m[31m. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Hypertension and Angina Pectoris Due to[0m
[31mCoronary Atherosclerosis Clinical studies of atenolol did not include sufficient number of patients aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger subjects. Other reported[0m
[31mclinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the [0m
[31mlow end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. ATENOLOL: precautions: Acute [0m
[31mMyocardial Infarction Of the [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m patients with suspected acute myocardial infarction randomized to atenolol in the ISIS-[0m[1;31m1[0m[31m trial [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY [0m[1;31m)[0m[31m, [0m[1;31m33[0m[31m% [0m[1;31m([0m[1;31m2[0m[31m,[0m[1;31m644[0m[1;31m)[0m[31m were [0m[1;31m65[0m[31m years of age and [0m
[31molder. It was not possible to identify significant differences in efficacy and safety between older and younger patients; however, elderly patients with systolic blood pressure [0m[1;31m<[0m[1;31m120[0m[31m mmHg seemed less [0m
[31mlikely to benefit [0m[1;31m([0m[31msee INDICATIONS AND USAGE [0m[1;31m)[0m[31m. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting greater frequency [0m
[31mof decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Evaluation of patients with hypertension or myocardial infarction should always include assessment [0m
[31mof renal function.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: dosage_and_administration: DOSAGE AND ADMINISTRATION Hypertension: The initial dose of atenolol is [0m[1;31m50[0m[31m mg given as one tablet a day either alone or added to diuretic therapy. The [0m
[31mfull effect of this dose will usually be seen within one to two weeks. If an optimal response is not achieved, the dosage should be increased to atenolol [0m[1;31m100[0m[31m mg given as one tablet a day. Increasing [0m
[31mthe dosage beyond [0m[1;31m100[0m[31m mg a day is unlikely to produce any further benefit. Atenolol may be used alone or concomitantly with other antihypertensive agents including thiazide-type diuretics, [0m
[31mhydralazine, prazosin, and alpha-methyldopa. Angina Pectoris The initial dose of atenolol is [0m[1;31m50[0m[31m mg given as one tablet a day. ATENOLOL: dosage_and_administration: If an optimal response is not [0m
[31machieved within one week, the dosage should be increased to atenolol [0m[1;31m100[0m[31m mg given as one tablet a day. Some patients may require a dosage of [0m[1;31m200[0m[31m mg once a day for optimal effect. Twenty-four hour [0m
[31mcontrol with once daily dosing is achieved by giving doses larger than necessary to achieve an immediate maximum effect. The maximum early effect on exercise tolerance occurs with doses of [0m[1;31m50[0m[31m to [0m[1;31m100[0m[31m [0m
[31mmg, but at these doses the effect at [0m[1;31m24[0m[31m hours is attenuated, averaging about [0m[1;31m50[0m[31m% to [0m[1;31m75[0m[31m% of that observed with once a day oral doses of [0m[1;31m200[0m[31m mg. Acute Myocardial Infarction In patients with definite or [0m
[31msuspected acute myocardial infarction, treatment with atenolol injection should be initiated as soon as possible after the patient's arrival in the hospital and after eligibility is established. Such [0m
[31mtreatment should be initiated in a coronary care or similar unit immediately after the patient's hemodynamic condition has stabilized. ATENOLOL: dosage_and_administration: Treatment should begin with [0m
[31mthe intravenous administration of [0m[1;31m5[0m[31m mg atenolol over [0m[1;31m5[0m[31m minutes followed by another [0m[1;31m5[0m[31m mg intravenous injection [0m[1;31m10[0m[31m minutes later. Atenolol injection should be administered under carefully controlled [0m
[31mconditions including monitoring of blood pressure, heart rate, and electrocardiogram. Dilutions of atenolol injection in Dextrose Injection USP, Sodium Chloride Injection USP, or Sodium Chloride and [0m
[31mDextrose Injection may be used. These admixtures are stable for [0m[1;31m48[0m[31m hours if they are not used immediately. In patients who tolerate the full intravenous dose [0m[1;31m([0m[1;31m10[0m[31m mg[0m[1;31m)[0m[31m, atenolol tablets [0m[1;31m50[0m[31m mg should be [0m
[31minitiated [0m[1;31m10[0m[31m minutes after the last intravenous dose followed by another [0m[1;31m50[0m[31m mg oral dose [0m[1;31m12[0m[31m hours later. Thereafter, atenolol can be given orally either [0m[1;31m100[0m[31m mg once daily or [0m[1;31m50[0m[31m mg twice a day for a [0m
[31mfurther [0m[1;31m6[0m[31m to [0m[1;31m9[0m[31m days or until discharge from the hospital. ATENOLOL: dosage_and_administration: If bradycardia or hypotension requiring treatment or any other untoward effects occur, atenolol should be[0m
[31mdiscontinued [0m[1;31m([0m[31msee full prescribing information prior to initiating therapy with atenolol tablets[0m[1;31m)[0m[31m. Data from other beta blocker trials suggest that if there is any question concerning the use of IV [0m
[31mbeta blocker or clinical estimate that there is a contraindication, the IV beta blocker may be eliminated and patients fulfilling the safety criteria may be given atenolol tablets [0m[1;31m50[0m[31m mg twice daily or[0m
[1;31m100[0m[31m mg once a day for at least seven days [0m[1;31m([0m[31mif the IV dosing is excluded[0m[1;31m)[0m[31m. Although the demonstration of efficacy of atenolol is based entirely on data from the first seven postinfarction days, data [0m
[31mfrom other beta blocker trials suggest that treatment with beta blockers that are effective in the postinfarction setting may be continued for one to three years if there are no contraindications. [0m
[31mATENOLOL: dosage_and_administration: Atenolol is an additional treatment to standard coronary care unit therapy. Elderly Patients or Patients with Renal Impairment Atenolol is excreted by the kidneys;[0m
[31mconsequently dosage should be adjusted in cases of severe impairment of renal function. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the [0m
[31mdosing range, reflecting greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. Evaluation of patients with hypertension or myocardial [0m
[31minfarction should always include assessment of renal function. Atenolol excretion would be expected to decrease with advancing age. No significant accumulation of atenolol occurs until creatinine [0m
[31mclearance falls below [0m[1;31m35[0m[31m mL/min/[0m[1;31m1.[0m[31m73m [0m[1;31m2[0m[31m . Accumulation of atenolol and prolongation of its half-life were studied in subjects with creatinine clearance between [0m[1;31m5[0m[31m and [0m[1;31m105[0m[31m mL/min. ATENOLOL: [0m
[31mdosage_and_administration: Peak plasma levels were significantly increased in subjects with creatinine clearances below [0m[1;31m30[0m[31m mL/min. The following maximum oral dosages are recommended for elderly, [0m
[31mrenally-impaired patients and for patients with renal impairment due to other causes: Creatinine Clearance [0m[1;31m([0m[31mmL/min/[0m[1;31m1.[0m[31m73m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m Atenolol Elimination Half-Life [0m[1;31m([0m[31mh[0m[1;31m)[0m[31m Maximum Dosage [0m[1;31m15[0m[31m-[0m[1;31m35[0m[31m [0m[1;31m16[0m[31m-[0m[1;31m27[0m[31m [0m[1;31m50[0m[31m mg daily [0m
[31m<[0m[1;31m15[0m[31m >[0m[1;31m27[0m[31m [0m[1;31m25[0m[31m mg daily Some renally impaired or elderly patients being treated for hypertension may require a lower starting dose of atenolol: [0m[1;31m25[0m[31m mg given as one tablet a day. If this [0m[1;31m25[0m[31m mg dose is used,[0m
[31massessment of efficacy must be made carefully. This should include measurement of blood pressure just prior to the next dose [0m[1;31m([0m[31m"trough"[0m[31m blood pressure[0m[1;31m)[0m[31m to ensure that the treatment effect is present [0m
[31mfor a full [0m[1;31m24[0m[31m hours. ATENOLOL: dosage_and_administration: Although a similar dosage reduction may be considered for elderly and/or renally impaired patients being treated for indications other than [0m
[31mhypertension, data are not available for these patient populations. Patients on hemodialysis should be given [0m[1;31m25[0m[31m mg or [0m[1;31m50[0m[31m mg after each dialysis; this should be done under hospital supervision as [0m
[31mmarked falls in blood pressure can occur. Cessation of Therapy in Patients with Angina Pectoris If withdrawal of atenolol therapy is planned, it should be achieved gradually and patients should be [0m
[31mcarefully observed and advised to limit physical activity to a minimum.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects have been mild and transient. The frequency estimates in the following table were derived from controlled studies in [0m
[31mhypertensive patients in which adverse reactions were either volunteered by the patient [0m[1;31m([0m[31mUS studies[0m[1;31m)[0m[31m or elicited, e.g., by checklist [0m[1;31m([0m[31mforeign studies[0m[1;31m)[0m[31m. The reported frequency of elicited adverse [0m
[31meffects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship[0m
[31mto atenolol is uncertain. Volunteered [0m[1;31m([0m[31m US Studies [0m[1;31m)[0m[31m Total-Volunteered and Elicited [0m[1;31m([0m[31m Foreign + US Studies [0m[1;31m)[0m[31m Atenolol [0m[1;31m([0m[31mn = [0m[1;31m164[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m206[0m[1;31m)[0m[31m % Atenolol [0m[1;31m([0m[31mn = [0m[1;31m399[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m407[0m[1;31m)[0m[31m % [0m
[31mCARDIOVASCULAR Bradycardia [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m Cold Extremities [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m [0m
[31mVertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Tiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m
[31mGASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute [0m
[31mmyocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to [0m
[31matropine and/or to withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and [0m
[31mother events occurring during these investigations is given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either [0m
[31mintravenous and/or oral atenolol administration: Conventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m
[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m
[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mNonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m
[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m Pulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m [0m
[31mpatients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for [0m
[31mReduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[31m< [0m[1;31m5[0m[31m mg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m
[31mCardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with atenolol [0m
[32mshould be initiated as soon as the patient's clinical condition allows. In the International Study of Infarct Survival [0m[1;32m([0m[32mISIS-[0m[1;32m1[0m[1;32m)[0m[32m, which included over [0m[1;32m16[0m[32m,[0m[1;32m000[0m[32m patients, atenolol was used to treat [0m
[32mpatients with acute myocardial infarction, suggesting a benefit in reducing cardiovascular mortality.[0m

[32mSOURCE: ATENOLOL label[0m
[32mEXTRACT_START_END: Atenolol is indicated in the management[0m[32m...[0m[32m to reduce cardiovascular mortality.[0m
*[1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Atenolol is indicated in the management of [0m
[34mhemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with atenolol should be initiated as soon as the patient's clinical[0m
[34mcondition allows. In the International Study of Infarct Survival [0m[1;34m([0m[34mISIS-[0m[1;34m1[0m[1;34m)[0m[34m, which included over [0m[1;34m16[0m[34m,[0m[1;34m000[0m[34m patients, atenolol was used to treat patients with acute myocardial infarction, suggesting a [0m
[34mbenefit in reducing cardiovascular mortality.[0m

[34mSOURCE: ATENOLOL label[0m
[34mEXTRACT_START_END: Atenolol is indicated in the management[0m[34m...[0m[34m to reduce cardiovascular mortality.[0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ATENOLOL increases or decreases the risk of mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded by stating that Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular [0m
[32mmortality. The International Study of Infarct Survival [0m[32m([0m[32mISIS-1[0m[32m)[0m[32m, which included over 16,000 patients, used atenolol to treat patients with acute myocardial infarction, suggesting a benefit in reducing[0m
[32mcardiovascular mortality."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"ATENOLOL decreases the risk of mortality after myocardial infarction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ATENOLOL increase or decrease the risk of mortality after myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ATENOLOL increases or decreases the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded by stating that Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular [0m
[34mmortality. The International Study of Infarct Survival [0m[34m([0m[34mISIS-1[0m[34m)[0m[34m, which included over 16,000 patients, used atenolol to treat patients with acute myocardial infarction, suggesting a benefit in reducing[0m
[34mcardiovascular mortality."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"ATENOLOL decreases the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ATENOLOL increase or decrease the risk of mortality after myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ATENOLOL increases or decreases the risk of mortality after myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded by stating that Atenolol is indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular [0m
[31mmortality. The International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m, which included over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m patients, used atenolol to treat patients with acute myocardial infarction, suggesting a benefit in reducing[0m
[31mcardiovascular mortality.[0m
[31m        -----[0m
[31m        Final answer: ATENOLOL decreases the risk of mortality after myocardial infarction.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mATENOLOL decreases the risk of mortality after myocardial infarction. This is based on the information provided by FDAHandler, which states that Atenolol is indicated for the management of [0m
[32mhemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. The International Study of Infarct Survival [0m[1;32m([0m[32mISIS-[0m[1;32m1[0m[1;32m)[0m[32m, which included over [0m
[1;32m16[0m[32m,[0m[1;32m000[0m[32m patients, used atenolol to treat patients with acute myocardial infarction, suggesting a benefit in reducing cardiovascular mortality.[0m
